CXCR4 Antibody (Dana-Farber patent anti-CXCR4) [Janelia Fluor® 525]
Novus Biologicals, part of Bio-Techne | Catalog # NBP3-28800JF525
Recombinant Monoclonal Antibody
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
ELISA, Flow Cytometry, Functional
Label
Janelia Fluor 525
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Dana-Farber patent anti-CXCR4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
CXCR4 / CD184
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Applications for CXCR4 Antibody (Dana-Farber patent anti-CXCR4) [Janelia Fluor® 525]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Functional
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: CXCR4
Long Name
C-X-C Motif Chemokine Receptor 4
Alternate Names
CD184, D2S201E, FB22, Fusin, HM89, HSY3RR, LAP-3, LAP3, LCR1, LESTR, NPY3R, NPYRL, NPYY3R, WHIMS
Gene Symbol
CXCR4
Additional CXCR4 Products
Product Specific Notices for CXCR4 Antibody (Dana-Farber patent anti-CXCR4) [Janelia Fluor® 525]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...